CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. (“Dimension” or the “Company”), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the appointment of several senior executives to its management team. The addition of these newly created positions is intended to complement the continued growth of Dimension’s programs and pipeline as the Company prepares to launch its first clinical trial and advances additional programs toward the clinic. The new appointments are: Julie Lin, M.D., M.P.H., Head of Rare Disease Clinical Development; Allen M. Poma, M.D., Head of Hematology Clinical Development; Janet C. Rae, RAC, Head of Rare Disease Regulatory Affairs; Ying Jing, Ph.D., Head of Upstream Process Development; Deborah Geraghty, Ph.D., Head of Commercial and Portfolio Strategy, and Andy Hu, M.D., Head of Business Development.
Annalisa Jenkins, Chief Executive Officer of Dimension, said, "Our portfolio of liver-directed gene therapy programs is advancing towards the clinic and multiple regulatory milestones. The appointments of these exceptionally talented and experienced individuals signal the Company's continued focus on operational excellence in manufacturing and global clinical development in rare disease. I speak for our entire team in noting how thrilled we are with the momentum at Dimension and our ability to attract leading talent in our industry.”
Julie Lin, M.D., M.P.H., joins Dimension as Head of Rare Disease Clinical Development, bringing extensive pharmaceutical experience in clinical development and drug safety from early development through post-marketing. Previously, Dr. Lin was Medical Director, Clinical Development at Genzyme Corp. In this role, she served as the global medical lead in nephrology pre-clinical and clinical development programs. Prior to Genzyme, Dr. Lin was Senior Medical Scientist, Global Safety at Amgen, Inc., also serving as Associate Physician at Brigham and Women's Hospital and founding the Outpatient Native Kidney Biopsy service. She also was an Assistant Professor of Medicine at Harvard Medical School. Dr. Lin received her A.B. in Biology at Harvard University; her M.D. Columbia University, College of Physicians and Surgeons, and her M.P.H. in Clinical Effectiveness at the Harvard School of Public Health.
Allen M. Poma, M.D., joins as Head of Hematology Clinical Development, bringing with him nearly a decade of experience in the healthcare industry. Prior to joining Dimension, Dr. Poma served as Senior Director of Medical Development at TESARO Inc., where he was responsible for the Clinical Development strategy for their lead product Rolapitant. Previously, he was Director, Clinical Research, at AMAG Pharmaceuticals, and served as Medical Director of Stryker Corporation, where he was responsible for the medical assessment of early stage products considered for in-licensing. During Dr. Poma’s eight-year tenure at Yale School of Medicine, he held positions including Assistant Clinical Professor, Division of Emergency Medicine, with the Department of Surgery. Dr. Poma received his B.A. in Biology at the University of North Carolina, Chapel Hill, his M.D. at Wake Forest School of Medicine, and his MBA in Finance at Columbia School of Business.
Janet C. Rae, RAC, is Head of Rare Disease, Regulatory Affairs, bringing with her extensive experience in the biotechnology and pharmaceutical industry, including rare disease product development and post marketing programs. Prior to joining Dimension, Ms. Rae held leadership positions at Shire Pharmaceuticals, including Director, Regulatory Affairs, and most recently, Global Regulatory Lead in Rare Diseases. In this latter role, she was responsible for the development and execution of regulatory strategies for Shire therapies within North America. Prior to this, Ms. Rae served as Sr. Director, Regulatory Affairs at Bentley Pharmaceuticals Inc. Previously, she held a series of leadership positions during her tenure at PAREXEL International, most recently serving as Consultant, Global Regulatory Affairs. Ms. Rae received her B.A. at Gordon College and her Regulatory Affairs Certification in November 2002.
Ying Jing, Ph.D., is Head of Upstream Process Development at Dimension and brings extensive biologics process development and manufacturing experience. Previously, Dr. Jing was Senior Scientist III at AbbVie Bioresearch Center, where she led the cell culture process development from bench to bedside, supporting regulatory and commercial manufacturing efforts. Prior to this, she served as Project Engineer, Biologics Development, at Bristol-Myers Squibb Company, and she also served as Senior Scientist in Chemical Development at Wyeth Pharmaceuticals. Dr. Jing received her B.S. at Tianjin University, an M.S. in Analytical Chemistry at Nankai University, and a Ph.D. in Chemical and Biomolecular Engineering from The Ohio State University.
Deb Geraghty, Ph.D., joined Dimension as Head of Commercial and Portfolio Strategy. Prior to Dimension, Dr. Geraghty was Founder and Vice President, Project and Portfolio Development, at Cydan Development, an orphan drug accelerator that raised $26 million to identify and de-risk assets with therapeutic and commercial potential. Previously, she was Head of Portfolio Advancement at Aileron Therapeutics, where she led strategic growth and commercial efforts. Prior to this, Dr. Geraghty was Director, New Product Marketing, at Infinity Pharmaceuticals. She also founded Back Bay Strategies, and worked at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corporation. Dr. Geraghty serves on the medical and scientific advisory board of Global Genes, a leading rare disease patient advocacy organization. She earned a B.S. in Biology at Union College, an MBA from the Carroll School at Boston College, and a Ph.D. in Molecular Biology at the University of Vermont.
Andy Hu, M.D., joined Dimension as of Head of Business Development. Dr. Hu brings diverse experience in corporate finance, strategy, and business development across the life sciences industry. Previously, he was Senior Director, Business Development, at Cubist Pharmaceuticals, where he was part of the transaction teams responsible for the acquisitions of Trius Therapeutics and Optimer Pharmaceuticals. Prior to this, Dr. Hu served as Vice President of Business Development and Strategy at Predictive Biosciences, Inc., a venture capital-backed developer and marketer of cancer diagnostic tests focused on urologic oncology. He also previously worked as part of the investment banking team at Leerink Partners, where he was part of deal teams which successfully executed over $600 million in equity financings for public and private life sciences companies, and as a Senior Consultant at Strategic Decisions Group. Dr. Hu received his A.B. in Environmental Science and Public Policy from Harvard University, an M.D. from Baylor College of Medicine, and an MBA from the Jones Graduate School of Management at Rice University.
About Dimension Therapeutics
Dimension Therapeutics, Inc., is a leading rare disease company focused on developing novel treatments for devastating disorders associated with the liver and based on an industry-leading, extensively validated adeno-associated virus (AAV) platform. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple best-in-class AAV vectors from REGENXBIO, which founded Dimension with Fidelity Biosciences in October 2013. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. For more information, please visit www.dimensiontx.com.